Lassativi

Sostanze sia di estrazione vegetale che di sintesi chimica, classificabili in base al loro meccanismo d’azione o in base alle caratteristiche chimico-fisiche delle molecole costitutive e della nota o presunta azione farmacologica, capaci di stimolare lo svuotamento del colon-retto. Vedi Alvo, Stipsi.

Tab. 4: Classificazione sinottica dei lassativi per metodo di azione

LASSATIVI FORMANTI MASSA
Aumentano il volume del residuo solido non assorbibile
Metilcellulosa; sterculia; agar; crusca; isphagula; psyllium, PHGG

LASSATIVI OSMOTICI NON SALINI
Aumentano il contenuto di acqua nell’intestino
Carboidrati non assorbibili (lattulosio, sorbitolo, mannitolo)

LASSATIVI OSMOTICI SALINI
Aumentano il contenuto di acqua nelle feci
Purganti salini (fosfato di sodio, solfato di magnesio, idrossido di magnesio);

LASSATIVI EMOLLIENTI
Modificano la consistenza delle feci
Docusato di sodio Olio di ricino Glicerina

LASSATIVI STIMOLANTI
Aumentano la motilità e la secrezione intestinale
Derivati del difenilmetano (Fenolftalenia, Bisacodile);
Derivati dell’Antrachinone (Senna, Cascara)

Tab. 5: LASSATIVI: dosaggi consigliati (esclusi emollienti) *

CLASSE: FORMANTI MASSA
NOME: Crusca
Psyllium (Psyllogel, Planten,
Psylloplus, Plantalax, ..)
DOSAGGIO: 2 buste al dì
NOME: Ispagula (Fibrolax)
DOSAGGIO: 3 bustine al dì
NOME: PHGG (Benefibra)
DOSAGGIO: 1 busta al dì (5 gr)

OSMOTICI
NOME: Polietilenglicole (Selg, Isocolan,
Movicol, ..)
DOSAGGIO: 17 gr/die
NOME: Lattulosio (Laevolac)
DOSAGGIO: 30 ml/die
NOME: Lattitolo (Portolac)
DOSAGGIO: 20 gr/die

SALINI
NOME: Solfato di magnesio
DOSAGGIO: 15 gr/die
NOME: Citrato di magnesio
DOSAGGIO: 200 ml/die

STIMOLANTI
NOME: Senna (Pursennid)
DOSAGGIO: 4 cpr/die
NOME: Bisacodile (Verecolene, Alaxa)
DOSAGGIO: 10 gr/die

* La tab. è fortemente incompleta, appena sufficiente a dare l’idea della difficoltà a bene
utilizzare i prodotti commerciali. I nomi tra parentesi sono commercialmente registrati.

  1. Lisi DM. Drug-induced constipation [letter; comment]. Archives of Internal Medicine 1946;154:461;
  2. Lantner RR et Al. Anaphylaxis following ingestion of a psyllium-containing cereal. JAMA 1990;264(19):2534-6;
  3. James JM et Al. Anaphylactic reactions to a psyllium containing cereal J Allergy Clin Immunol 1991;88:402-8;
  4. Malo JL. Prevalence of occupational asthma and immunologic sensitization to psyllium among health personnel in chronic care hospitals. Am Rev Resp Dis 1990;142:1359-66;
  5. Freeman GL. Psyllium hypersensitivity Ann Allergy 1994;73(6):490-2;
  6. Shelling JR. Fatal hypermagnesemia. Clin Neprhol 2000;53(1):61-5; Plantalax, ..)
  7. Fed Regist. Package size limitation for sodium phosphates oral solution and warning and direction statements for oral and rectal sodium phosphates for over-the-counter laxative use. Food and Drug Adiminstration; HHS. Final rule 1998; 62(98):27836-44;
  8. Driman DK et Al. Colorectal inflammation and increased cell proliferation associated with oral sodium phosphate bowel preparation solution. Hum Pathol 1998;46 (3):255-61;
  9. Gattuso JM, Kamm MA. Adverse effects of drugs used in the manegement of constipation and diarrhoea. Drug Saf 1994; 10:47-65;
  10. Joo S et Al. Alterations in colonic anatomy induced by chronic stimulant laxatives: the cathartic colon revisited. J Clin Gastroenterol
    1998;26(4): 283-6;
  11. Garner J, et al. Phenolpthtalein metabolite inhibits cathechol-O-methyltransferase-mediated metabolism of catechol estrogen: a possible mechanism for carcinogenety. Toxicol Appl Pharmacol 2000;162(2):124-31;
  12. Fed Regist. Laxative drug products for over-the-counter humane use. Food and Drug Administration; HHS. Final rule 1999;64(19):
    4535-40;
  13. van Gorkom et Al. Review article: anthranoid laxatives and their potential carcinogenic effects. Aliment Pharmacol Ther 1999;13(4):
    443-52;
  14. Shorkuber M et Al Effect of anthraquinone-laxatives on the proliferation and urokinase secretion of normal, premalignant and malignant colonic epithelial cells. Eur J Cancer 1998; 4(7):1091-8;
  15. van Gorkom BA et Al. Influence of highly purifed senna exract on colonic epithelium. Digestion 2000; 61(2):113-20;
  16. Muller-Lissner S. Classification, pharmacology, and side effects of common laxatives. Ital J Gastroenterol Hepatol 1999;31:S234-7;
  17. Anonymous. Gastrointestinal Diseases drug therapy for constipation. In: McCormack, J., (Ed.) Drug Therapy: decision making guide, (1996) pp. 60-64. W.B.Saunders & Co;
  18. Beach RC. Management of childhood constipation. Lancet 1996;348:766-767;
  19. Fallon M, O’Neill B. Constipation and diarrhoea. BMJ 1997;315:1293-1296;
  20. Gallagher B,, West D,, Puntis JW, Stringer MD. Characteristics of children under 5 referred to hospital with constipation – a oneyear prospective study. Intern J Clin Pract 1998;52:165-167;
  21. Jewell D I, Young,G. Interventions for treating constipation in pregnancy. (Cochrane Review). The Cochrane Library (issue 2). 1999, Update Software.
  22. Kamm MA. Constipation. Medicine International 1994; 22:305-308;
  23. Lee A, Schofield S. Drug use in pregnancy: general principles. Pharmaceutical Journal 1994;253:27-30;
  24. McClung HJ, Boyne L, Heitlinger L. Constipation and dietary fiber intake in children. Pediatrics 1995;96:999-1000;
  25. Passmore AP, Wilson-Davies K, Stoker C, and et. Al. Chronic constipation in long stay elderly patients: a comparison of lactulose and a senna-fibre combination. BMJ 1993;307:769-771;
  26. Petticrew M, Watt I, Brand M. What’s the best buy for treatment of constipation? Results of a systematic review of the efficacy and comparative efficacy of laxatives in the elderly. British Journal of General Practice 1999;49:387-393;
  27. Petticrew M, Watt I, Sheldon T. Systematic review of the effectiveness of laxatives in the. elderly. Core Research, Alton on behalf of the National Coordinating Centre for Health Technology Assessment (1997), 1 (10);
  28. Spiller R. When fibre fails. British Medical Journal 1990;300:1064-5;
  29. Tramonte SM, and et al. The treatment of chronic constipation in adults: a systematic review, The Cochrane Database of Systematic Reviews. 1997;
  30. Abyad A, Mourad F. Constipation; common sense care of the older patient. Geriatrics 1996;51:28-36;
  31. Anderson AS. Constipation in pregnancy: is your advice on diet effective? Professional Care of Mother & Child 1990; 6:87;
  32. Badiali D, Corazziari R, Habib FI, Tomei E, Bausano G, Magrini P, Anzimi F, Torsoli A. Effect of wheat bran in treatment of chronic nonorganic constipation. A double-blind controlled trial. Dig Dis Sci 1995;40:349-356;
  33. Lamazza A, et al. Water supplementation enhances the effect of high fibre diet on stool frequency and laxative consumption in adult patients with functional constipation. Hepatogastroenterol 1998;45:727-732;
  34. Passmore,AP, Davies KW, Scott ME. Chronic constipation in long stay elderly patients: a comparison of lactulose and a senna fibre combination. British Medical Journal 1993;307:769-71;
  35. Schutze K, Brandstatter G, Dragosics, B, Judmaier G. Hentschel E. Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome. Alim Pharmacol Ther 1997;11:387-394;
  36. Miles CL, Fellowes D, Goodman ML, Wilkinson S. Laxatives for the management of constipation in palliative care patients. Cochrane Database Syst Rev 2006;(4):CD003448
  37. Petticrew M, Watt I, Sheldon T. Systematic review of the effectiveness of laxatives in the elderly. Health Technol Assess. 1997;1(13):
    1-52;
  38. Prather CM. Pregnancy-related constipation. Curr Gastroenterol Rep. 2004;6(5):402-4.
  39. Schmulson Wasserman M, Francisconi C, Olden K, Aguilar Paíz L,et Al. The Latin-American Consensus on Chronic Constipation Gastroenterol Hepatol 2008;31(2):59-74.
  40. Rao SS, Seaton K, Miller M, Brown K, Nygaard I, Stumbo P, Zimmerman B, Schulze K. Randomized controlled trial of biofeedback, sham feedback, and standard therapy for dyssynergic defecation. Clin Gastroenterol Hepatol 2007;5(3):331-8;
  41. Wang HJ, Liang XM, Yu ZL, Zhou LY, Lin SR, Geraint M. A Randomised, Controlled Comparison of Low-Dose Polyethylene Glycol
    3350 plus Electrolytes with Ispaghula Husk in the Treatment of Adults with Chronic Functional Constipation. Clin Drug Investig
    2004;24(10):569-576;
  42. Singh B. Psyllium as therapeutic and drug delivery agent. Int J Pharm 2007;334(1-2):1-14;
  43. McRorie JW, Daggy BP, Morel JG, Diersing PS, Miner PB, Robinson M. Psyllium is superior to docusate sodium for treatment of
    chronic constipation. Aliment Pharmacol Ther 1998;12(5):491-7;
  44. Parisi G Bottona E, Carrara M Cardin F Faedo A Goldin D Marino M, Pantalenta M, Tafner G, Verdianelli G, Zilli M, Leandro G. Treatment Effects of Partially Hydrolyzed Guar Gum on Symptoms and Quality of Life of Patients with Irritable Bowel Syndrome. A Multicenter Randomized Open Trial. Dig Dis Sci 2005;50( 6):1107–12.
‹ Torna all'indice
Dizionario
Cerca medico
Centri U.C.P.
Informazioni per i Pazienti

Ultimo aggiornamento:

Stomie Cutanee
Leggi ›

L'Esperto Risponde

Stefano Mancini
stedoc@tiscalinet.it

Lettere al presidente

Dott. Francesco Selvaggi
Rubrica diretta a quanti volessero porre dei quesiti al Presidente SICCR, Dott. Francesco Selvaggi.

presidenza@siccr.org

Informazione pubblicitaria
Gloria-Med-PharmaNeopharmed-Gentili
Partner
AIGOAIUGCICSIUD